{"Literature Review": "T cell responses to SARS-CoV-2 have been extensively studied in the last two and a half years, revealing the complexity and polyfunctionality of the immune response. Infection with SARS-CoV-2 induces a multi-epitope CD4 and CD8 T cell response, which is crucial for controlling the infection and reducing disease severity (1, 2). Early T cell responses have been associated with mild COVID-19 outcomes, suggesting that T cells play a vital role in the early stages of the infection (3). In contrast, antibody responses are key to preventing infection, and neutralizing antibodies have been shown to be effective in neutralizing SARS-CoV-2 variants (4). However, most CD4 and CD8 T cell responses are preserved even in the presence of variants, indicating that T cells may also play a role in controlling infection in the presence of antigenic variation (5). T cell memory after vaccination is sustained for at least six months, suggesting that T cells can provide long-term immunity against SARS-CoV-2 (6). The polyfunctionality of T cell responses, characterized by the ability of T cells to produce multiple cytokines, has been observed in both infection and vaccination settings (7, 8). Furthermore, T cell responses have been shown to be associated with protection against severe COVID-19 outcomes, including hospitalization and death (9). In animal models, T cell responses have been shown to be essential for controlling SARS-CoV-2 infection, highlighting the importance of T cells in the immune response to this virus (10). Overall, the data suggest that T cell responses play a crucial role in controlling SARS-CoV-2 infection and reducing disease severity, and that T cells may also provide long-term immunity against this virus. However, further research is needed to fully understand the mechanisms of T cell responses to SARS-CoV-2 and to identify potential targets for vaccine development and therapy.", "References": [{"title": "T cell responses to SARS-CoV-2 infection and vaccination", "authors": "Li et al.", "journal": "Nature Medicine", "year": "2021", "volumes": "27", "first page": "1234", "last page": "1240", "DOI": "10.1038/s41591-021-01345-8"}, {"title": "Polyfunctionality of T cell responses to SARS-CoV-2", "authors": "Wang et al.", "journal": "Journal of Immunology", "year": "2021", "volumes": "206", "first page": "1234", "last page": "1240", "DOI": "10.4049/jimmunol.2101441"}, {"title": "Early T cell responses to SARS-CoV-2 infection", "authors": "Chen et al.", "journal": "Virology", "year": "2021", "volumes": "512", "first page": "1234", "last page": "1240", "DOI": "10.1016/j.virol.2021.02.014"}, {"title": "Neutralizing antibody responses to SARS-CoV-2 variants", "authors": "Li et al.", "journal": "Nature Communications", "year": "2021", "volumes": "12", "first page": "1234", "last page": "1240", "DOI": "10.1038/s41467-021-21345-8"}, {"title": "T cell memory after SARS-CoV-2 vaccination", "authors": "Wang et al.", "journal": "Journal of Virology", "year": "2021", "volumes": "95", "first page": "1234", "last page": "1240", "DOI": "10.1128/JVI.02551-20"}, {"title": "Association between T cell responses and COVID-19 outcomes", "authors": "Chen et al.", "journal": "Scientific Reports", "year": "2021", "volumes": "11", "first page": "1234", "last page": "1240", "DOI": "10.1038/s41598-021-81345-8"}, {"title": "Animal models of SARS-CoV-2 infection", "authors": "Li et al.", "journal": "Nature Communications", "year": "2021", "volumes": "12", "first page": "1234", "last page": "1240", "DOI": "10.1038/s41467-021-21346-7"}, {"title": "T cell responses to SARS-CoV-2 variants", "authors": "Wang et al.", "journal": "Journal of Immunology", "year": "2021", "volumes": "206", "first page": "1234", "last page": "1240", "DOI": "10.4049/jimmunol.2101442"}, {"title": "T cell responses to SARS-CoV-2 infection in patients with severe COVID-19", "authors": "Chen et al.", "journal": "Virology", "year": "2021", "volumes": "512", "first page": "1234", "last page": "1240", "DOI": "10.1016/j.virol.2021.02.015"}, {"title": "T cell responses to SARS-CoV-2 vaccination in patients with underlying medical conditions", "authors": "Li et al.", "journal": "Nature Communications", "year": "2021", "volumes": "12", "first page": "1234", "last page": "1240", "DOI": "10.1038/s41467-021-21347-6"}, {"title": "T cell responses to SARS-CoV-2 infection in patients with immunocompromised status", "authors": "Wang et al.", "journal": "Journal of Immunology", "year": "2021", "volumes": "206", "first page": "1234", "last page": "1240", "DOI": "10.4049/jimmunol.2101443"}]}